PHK
RNAC icon

Point72 Hong Kong’s Cartesian Therapeutics RNAC Stock Holding History

Point72 Hong Kong’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-74
Closed -$4K – 1361
2022
Q3 		$4K Buy
+74
New +$4.06K ﹤0.01% 1813
2022
Q2 		– Sell
-634
Closed -$23K – 2337
2022
Q1 		$23K Buy
634
+452
+248% +$28.3K ﹤0.01% 1508
2021
Q4 		$18K Sell
182
-9
-5% -$968 ﹤0.01% 1562
2021
Q3 		$24K Buy
+191
New +$23.1K ﹤0.01% 1666
2021
Q1 		– Sell
-172
Closed -$16K – 2148
2020
Q4 		$16K Buy
172
+17
+11% +$1.47K ﹤0.01% 1467
2020
Q3 		$11K Buy
+155
New +$11.9K ﹤0.01% 975
2018
Q1 		– Sell
-5
Closed -$1K – 1110
2017
Q4 		$1K Buy
+5
New +$2.19K ﹤0.01% 778
2017
Q3 		– Sell
-6
Closed -$4K – 1020
2017
Q2 		$4K Buy
+6
New +$2.65K ﹤0.01% 591

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Hong Kong's RNAC Position: Q4 2022 in Review

Point72 Hong Kong sold out of Cartesian Therapeutics (RNAC) in Q4 2022, closing a stake of 74 shares — an estimated $4K sold.

Point72 Hong Kong first reported a position in RNAC in Q2 2017 and held it in 8 quarters. The position peaked at $24K in Q3 2021. 84 funds tracked by Wall St. Rank hold RNAC as of Q4 2022.

  • Point72 Hong Kong reported no remaining Cartesian Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 74 Cartesian Therapeutics shares in Q4 2022, an estimated $4K.
  • Point72 Hong Kong first reported a position in Cartesian Therapeutics in Q2 2017 and held it in 8 quarters.
  • Point72 Hong Kong's Cartesian Therapeutics position peaked at $24K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.